Growth and Innovation

Our expenses for research and development rose by 14.1% (Fx adj.) in the first nine months of 2015 to €3,023 million (9M 2014: €2,520 million), including €1,041 million (Fx adj. +15.1%) in the third quarter (Q3 2014: €867 million). Capital expenditures for property, plant and equipment and intangible assets in the first nine months of 2015 amounted to €1,599 million (9M 2014: €1,427 million), including €654 million in the third quarter (Q3 2014: €544 million).

Research and Development Expenses in the First Nine Months of 2015

Subgroup shares in parentheses

Research and Development Expenses in the First Nine Months of 2015 (pie chart)Research and Development Expenses in the First Nine Months of 2015 (pie chart)
Capital Expenditures in the First Nine Months of 2015

Subgroup shares in parentheses

Capital Expenditures in the First Nine Months of 2015 (pie chart)Capital Expenditures in the First Nine Months of 2015 (pie chart)

Sales in the Emerging Markets1 advanced by 6.7% (Fx adj.) to €12,658 million in the first nine months of 2015 (9M 2014: €11,301 million), including €4,270 million in the third quarter (Fx adj. +1.7%; Q3 2014: €4,103 million). The Emerging Markets’ share of total sales was down slightly against the prior-year period at 36.2% (9M 2014: 37.0%). The respective figure for the third quarter of 2015 was 38.7% (Q3 2014: 41.2%).

Sales Development in the First Nine Months of 2015

Currency-adjusted changes in parentheses

Sales Development in the First Nine Months of 2015 (pie chart)Sales Development in the First Nine Months of 2015 (pie chart)

1 For reporting purposes we have defined the Emerging Markets as Asia (excluding Japan), Latin America, Eastern Europe, Africa and the Middle East.